Market Access News | pharmaphorum

News

BMS gets US approval for ROS1 lung cancer drug Augtyro

Bristol-Myers Squibb has secured FDA approval for Augtyro, a lung cancer therapy it acquired as part of its $4.1 billion takeover of Turning Point Therapeutics last year t

News

UK first to approve Vertex, CRISPR drug for blood disorders

The first-ever CRISPR-based gene-editing therapy has been approved for marketing in the UK for inherited blood disorders sickle cell disease (SCD) and transfusion-dependen

News

UK may add chickenpox to routine child vaccinations

Scientific advisors in the UK have recommended that all children should be given two doses of varicella (chickenpox) vaccine, saying fears that doing so could lead to more

News

UCB on course for approval of gMG drug Rystiggo in EU

UCB’s efforts to build a franchise of therapies for muscle-wasting disease generalised myasthenia gravis have taken another step forwards after the CHMP recommended approv

News

CHMP backs GSK’s momelotinib for myelofibrosis

GSK is on the brink of EU approval for JAK inhibitor momelotinib as a treatment for myelofibrosis patients with anaemia, after the EMA’s human medicines committee issued a

News

Takeda gets okay in US for rare blood disorder drug

Patients in the US with ultra-rare blood clotting disorder congenital thrombotic thrombocytopenic purpura (cTTP) have an FDA-approved therapy for the first time, after Tak

BMS gets US approval for ROS1 lung cancer drug Augtyro

UK first to approve Vertex, CRISPR drug for blood disorders

UK may add chickenpox to routine child vaccinations

UCB on course for approval of gMG drug Rystiggo in EU

CHMP backs GSK’s momelotinib for myelofibrosis

Takeda gets okay in US for rare blood disorder drug

J&J's oral IL-23 drug backed for psoriasis in EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks